Collecting data on chronic GVHD instances

The purpose of this research study is to explore the post-treatment barriers faced by adolescent and young adult (AYA) cancer survivors to therefore adapt the Needs Assessment and Service Bridge (NA-SB) tool produced by the UNC AYA Cancer Program. You are being asked to take part in a research study because you are an adolescent or young adult who has experienced cancer survivorship.

We would like to help patients identify what is important to them, i.e., their values, and support communicating that to their caregivers and healthcare providers. We are trying to create a tool that will make it easier to share what is most important to patients with metastatic breast cancer and their caregivers, with the patient's oncology healthcare provider.

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

You are being asked to participate in this research study because you have a type of tumor called a Central Nervous System (CNS) tumor, and you are scheduled to have surgery to remove this tumor. The study team wants to use left-over tumor samples from this surgery to study your tumor and test new ways to fight it.

This study is being done to answer the following question: Do two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating KS in PLWH in sub-Saharan Africa? We are doing this study because we want to find out if one of these approaches, PTX or PLD, is better than the other for KS. Both drugs may be given as part of the usual approach for your KS. The usual approach is defined as care most people get for KS.

This is an exploratory study in cancer biomarker research, hoping to identify cell-signaling using DNA, in patients with SCLC.

The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.

The purpose of this study is to determine if it is possible to identify biomarkers that tell us what type of response a person with metastatic breast cancer (MBC) will have to "antibody-drug conjugates" (ADCs).

The purpose of this study is to determine the safety of the addition of universal donor, expanded NK cells to gemcitabine/docetaxel for treatment of relapsed and refractory sarcomas.